Preclinical evidence that MNK/eIF4E inhibition by cercosporamide enhances the response to antiangiogenic TKI and mTOR inhibitor in renal cell carcinoma.

[1]  C. Wood,et al.  Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial. , 2020, European urology oncology.

[2]  N. Agarwal,et al.  First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. , 2019, European urology oncology.

[3]  C. Porta,et al.  Renal cell carcinoma treatment after first-line combinations. , 2019, The Lancet. Oncology.

[4]  M. Milik,et al.  Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors. , 2017, Current medicinal chemistry.

[5]  Charles Swanton,et al.  Renal cell carcinoma , 2017, Nature Reviews Disease Primers.

[6]  C. Porta,et al.  Choosing the right cell line for renal cell cancer research , 2016, Molecular Cancer.

[7]  Sien Guo,et al.  Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[8]  J. Seebacher,et al.  Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy. , 2016, Cellular signalling.

[9]  Sen Chen,et al.  Niclosamide suppresses renal cell carcinoma by inhibiting Wnt/β-catenin and inducing mitochondrial dysfunctions , 2016, SpringerPlus.

[10]  Sen Chen,et al.  Mefloquine effectively targets gastric cancer cells through phosphatase-dependent inhibition of PI3K/Akt/mTOR signaling pathway. , 2016, Biochemical and biophysical research communications.

[11]  J. Larkin,et al.  Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma , 2015, Molecular Cancer Therapeutics.

[12]  A. Reynolds,et al.  Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions , 2014, Angiogenesis.

[13]  J. Reeves,et al.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.

[14]  P. Iversen,et al.  Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors. , 2013, Blood.

[15]  J. Larkin,et al.  Current and future systemic treatments for renal cell carcinoma. , 2013, Seminars in cancer biology.

[16]  C. Proud,et al.  Targeting Mnks for Cancer Therapy , 2012, Oncotarget.

[17]  N. Sonenberg,et al.  Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. , 2011, Cancer research.

[18]  T. Mak,et al.  Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development , 2010, Proceedings of the National Academy of Sciences.

[19]  H. Kleinman,et al.  In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract , 2010, Nature Protocols.

[20]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[21]  S. Lowe,et al.  Dissecting eIF4E action in tumorigenesis. , 2007, Genes & development.

[22]  O. Larsson,et al.  Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors. , 2007, Cancer research.

[23]  S. Nagata,et al.  Mnk2 and Mnk1 Are Essential for Constitutive and Inducible Phosphorylation of Eukaryotic Initiation Factor 4E but Not for Cell Growth or Development , 2004, Molecular and Cellular Biology.

[24]  N. Sonenberg,et al.  Eukaryotic translation initiation factors and regulators. , 2003, Current opinion in structural biology.

[25]  W. Thoenes,et al.  Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. , 1986, Pathology, research and practice.

[26]  L. Platanias,et al.  Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia , 2017, Cytokine.

[27]  A. Gingras,et al.  eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. , 1999, Annual review of biochemistry.